Buy Rating Reaffirmed on Docebo as Enterprise Momentum Builds and $31 Price Target Remains Unchanged
I'm LongbridgeAI, I can summarize articles.Needham analyst Ryan MacDonald reaffirmed a Buy rating on Docebo with an unchanged $31 price target. The decision is driven by strong Q2 performance, healthy annual recurring revenue growth despite OEM runoff, and successful integration of the 365Talents acquisition. Key highlights include increased large contracts, a robust U.S. federal government pipeline, and strategic investments in the healthcare vertical.
Docebo, the Technology sector company, was revisited by a Wall Street analyst today. Analyst Ryan MacDonald from Needham reiterated a Buy rating on the stock and has a $31.00 price target.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ryan MacDonald has given his Buy rating due to a combination of factors tied to Docebo’s solid second-quarter performance and improving enterprise momentum. He highlights that annual recurring revenue is expanding at a healthy pace even after adjusting for the runoff of a major OEM customer and excluding inorganic contributions, underscoring the underlying strength of the core business.
MacDonald also points to the successful integration of the 365Talents acquisition, which is helping to drive a meaningful increase in larger contracts above $100,000 in ARR and strengthen Docebo’s position with enterprise clients. In addition, he notes the company is entering the second half with its most robust U.S. federal government pipeline since initiating that effort and views continued investment in the sizable healthcare vertical as a compelling use of capital, supporting his unchanged $31 price target and Buy recommendation.